Showing 2830 results
-
Ad hoc release /Ad hoc announcement pursuant to Art. 53 LRFirst quarterNet sales declined -5% (cc1, -1% USD), as growth drivers were more than offset by US generic erosionContinued strong performance from priority…
-
Ad hoc release /Ad hoc announcement pursuant to Art. 53 LR Itvisma (onasemnogene abeparvovec-brve) demonstrated improved motor function and stabilization in patients regardless of SMA treatment history in Phase III…
-
Press release /Expansion represents significant investment in North Carolina and is expected to create 700 new jobs in the state by end of 2030Enables manufacturing of medicines across company’s main therapeutic…
-
Press release /Phase III trial for KLU156 (ganaplacide/lumefantrine, or GanLum), meets primary endpoint of non-inferiority to standard of care Coartem® (artemether-lumefantrine) Demonstrates PCR-corrected cure rate…
-
Press release /At one-year mark, company has progressed all components of US investment plan to support delivery of innovative medicines to US patientsNew active pharmaceutical ingredients facility in North…
-
Event /Novartis announces the company’s financial results for the second quarter and first half of 2026.
-
Event /The Annual General Meeting takes place on Friday, March 6, 2026, 10:00 CET at St. Jakobshalle, St. Jakobs-Strasse 390, 4052 Basel, Switzerland.
-
Event /